[
    [
        {
            "time": "2019-01-18",
            "original_text": "Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Sarcoma",
                    "Treatment",
                    "Phase 3",
                    "Trial",
                    "Fails"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Highly Rated Pharma Dips On Drug Failure — Is Its Buy Point At Risk?",
            "features": {
                "keywords": [
                    "Pharma",
                    "Drug",
                    "Failure",
                    "Buy Point",
                    "Risk"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Highly Rated Pharma Dips On Drug Failure — Is Its Buy Point At Risk?",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "LLY",
                    "Stock",
                    "Falls",
                    "Sarcoma",
                    "Study",
                    "Failure"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Lilly cancer drug fails key trial, will no longer be prescribed",
            "features": {
                "keywords": [
                    "Lilly",
                    "Cancer",
                    "Drug",
                    "Fails",
                    "Key Trial",
                    "Prescribed"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly cancer drug fails key trial, will no longer be prescribed",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Lilly's Sarcoma Drug Combo Proves Ineffective in Trials",
            "features": {
                "keywords": [
                    "Lilly",
                    "Sarcoma",
                    "Drug",
                    "Combo",
                    "Ineffective",
                    "Trials"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly's Sarcoma Drug Combo Proves Ineffective in Trials",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Here is Why Growth Investors Should Buy Lilly (LLY) Now",
            "features": {
                "keywords": [
                    "Growth",
                    "Investors",
                    "Buy",
                    "Lilly",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here is Why Growth Investors Should Buy Lilly (LLY) Now",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "FDA Turns Down IMMU's Breast Cancer Drug, ZYME/LLY Deal Progresses, ZFGN Abuzz",
            "features": {
                "keywords": [
                    "FDA",
                    "IMMU",
                    "Breast Cancer",
                    "Drug",
                    "ZYME",
                    "LLY",
                    "Deal",
                    "Progresses",
                    "ZFGN",
                    "Abuzz"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "FDA Turns Down IMMU's Breast Cancer Drug, ZYME/LLY Deal Progresses, ZFGN Abuzz",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Dow jumps 160 points as stock market set to end week with solid gains on China-trade optimism",
            "features": {
                "keywords": [
                    "Dow",
                    "Jumps",
                    "Points",
                    "Stock Market",
                    "Solid Gains",
                    "China-Trade",
                    "Optimism"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "market"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow jumps 160 points as stock market set to end week with solid gains on China-trade optimism",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Lilly's cancer therapy Lartruvo fails study, shares drop",
            "features": {
                "keywords": [
                    "Lilly",
                    "Cancer",
                    "Therapy",
                    "Lartruvo",
                    "Fails",
                    "Study",
                    "Shares",
                    "Drop"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly's cancer therapy Lartruvo fails study, shares drop",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-01-18",
            "original_text": "Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Shares",
                    "Slide",
                    "Premarket",
                    "Failed",
                    "Trial",
                    "Sarcoma",
                    "Treatment"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        }
    ]
]